Health and Healthcare
Myriad's Alarming Alzheimer's Forecasts
Published:
Last Updated:
Myriad Genetics, Inc. (MYGN-NASDAQ) has issued a press release discussing a new study showing that the potential savings to the US healthcare system alone could be $4.0 Trillion from 2010 to 2050. It estimates that in 2030 the rate from today’s 5.1 million Americans with Alzheimer’s will grow to 7.7 million and then to 16 million by 2050.
What Myriad is doing is essentially promoting its Flurizan (currently in Phase II’s) and it is trying to speed things up by noting that the delay of even a year could have tremendous expense ramifications. We noted many of the other company names working in the sector after Barron’s ran a cover story on this epidemic that Barron’s left off.
These current numbers and projections are seeming to get worse and worse each year
Jon C. Ogg
May 15, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
